Publications by authors named "Malachi M Joiner"
Article Synopsis
- Neonates with congenital diaphragmatic hernia (CDH) often need cardiopulmonary bypass and anticoagulation therapy, but previous studies showed that even low doses of heparin can hinder lung growth and function.
- In an experiment on mice, heparin alone reduced lung endothelial cell proliferation and increased cell death, but the negative effects on proliferation could be mitigated with direct thrombin inhibitors (DTIs) like bivalirudin and argatroban.
- Despite these promising findings in vitro, the study concluded that DTIs did not sufficiently counteract the decreased lung growth associated with low-dose heparin in vivo, highlighting the need for clinical research on the combined effects of heparin and DTIs in
Background: Ethanol lock therapy (ELT) decreases central line-associated bloodstream infections; however, the effect on mechanical catheter complications is unclear. In recent years, ELT has become unavailable for many patients, often resulting in high-risk patients switching back to heparin locks. We investigated the impact of ELT on mechanical catheter complications during this period.
View Article and Find Full Text PDFArticle Synopsis
- Infants with congenital diaphragmatic hernia (CDH) may need cardiopulmonary bypass and anticoagulation, which can affect lung growth crucial for survival.
- Previous studies showed that heparin hampers lung development, whereas direct thrombin inhibitors (DTIs) like bivalirudin and argatroban promote lung growth.
- Research revealed that DTIs preserved lung function and growth in a mouse model, suggesting they might be better alternatives to heparin for CDH patients, warranting further clinical investigations.
Peripheral artery disease (PAD), the pathophysiologic narrowing of arterial blood vessels of the lower leg due to atherosclerosis, is a highly prevalent disease that affects more than 6 million individuals 40 years and older in the United States, with sharp increases in prevalence with age. Morbidity and mortality rates in patients with PAD range from 30% to 70% during the 5- to 15-year period after diagnosis and PAD is associated with poor health outcomes and reduced functionality and quality of life. Despite advances in medical, endovascular, and open surgical techniques, there is striking variation in care among population subgroups defined by sex, race and ethnicity, and socioeconomic status, with concomitant differences in preoperative medication optimization, amputation risk, and overall health outcomes.
View Article and Find Full Text PDF